This technology is a library of compounds designed to target key pathways of eye development that can be used to treat myopia.
Corrective lenses and refractive surgery can help patients overcome obstacles associated with vision loss caused by myopia. However, these approaches have minimal effects on the underlying elongation of the eye. Although pharmaceutical treatments for myopia are in development, the side effects associated with these treatments are considered unacceptable for long-term therapy.
This collection of compounds leverages important pathways in eye development to treat or prevent myopia. Using both targeted and systems genetics approaches, these compounds were prioritized based on their anti-myopic potential. Flexibility in the route of administration of these compounds, including topically via eye drops or via specialized contact lenses, limits potential side effects.
Patent Pending(WO/2021/247635)
Patent Pending(WO/2021/252626)
Patent Pending(WO/2021/252628)
IR CU20372, CU20378, CU20379, CU20382, CU20383, CU20384
Licensing Contact: Kristin Neuman